Chapel Hill, NC  ̶  January 4, 2018  ̶  Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, today announced that Principal Programmer/Analyst and Statistical Programming Operational Service Lead Kristen Harrington has been appointed to vice president of SESUG, a Regional Users Group (RUG) for users of SAS® Software. Her appointment term begins January 1, 2018.

In her role as vice president, Kristen will assist the president at their request and will temporarily act as president when immediate action is required and the president is not available. To qualify for the appointment of vice president, the person must be a prior SESUG conference co-chair. Kristen is currently the treasurer (term began Jan 1, 2017), has been a member of the Executive Council since 2014, and conference co-chair in 2016. She has attended, volunteered and presented at SESUG since 2007.

“I am truly honored to be representing SESUG and stepping into a larger role for the group,” said Kristen. “As a veteran user of SAS® software, I value my involvement with SESUG over the last 10 years in various roles, and I look forward to the ever growing continuing education and networking opportunities this conference encourages.”

Kristen has more than 18 years’ experience using SAS® software for data analysis including more than 15 years working in clinical trials and drug development.  At Rho, she serves as an internal expert in statistical programming and leads teams of statistical programmers.

To learn more about Rho, please visit www.rhoworld.com.

About Rho

Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 34 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. Please follow us on Twitter.